5Benzi GD,Bernardi M,Manzol L,et al.Effect of lysergide and nicergoline on glucose memtabolism investigated on the dog brain isolated in situ[].Journal of Pharmacological Sciences.1972
6Nagakawa Y,Akedo Y,Kaku S,et al.Effect of nicergoline on platelet aggregation,plasma viscosity and erythrocyte deformability in geriatric patients with cerebral infarction[].Arzneimittel Forschung Drug Research.1990
2Toyata T, Hirata Y, Tkeda Y, et al. Lipo - PGE1, a new lipidencapsulated preparation of prostaglandin E1: placebo and prostaglandin E1 controlled multicenter trials in patients with diabetic neuropathy and leg ulcers[J]. Prostaglandins 1993;46:453.
3Washinton C. Stability of lipid emulsion for drug delivery. Adv Drug Rev 1996; 20:131.
4陈晓云,杨庚明,赵义娟,等.前列地尔治疗糖尿病周围神经病变初步探讨 2000;31:545.
5 Carlson LA, OlssonAG. Intravenous prostaglandin E1 in severe peripheral vascular disease[J].Lancet, 1976, 9(7886)∶810
6 Shindo H,Tawata M,Inoue M,et al.The effect of prostaglandin E1 alphaCD on vibratory threshold determined with the SMV-5 vibrometer in patients with diabeticneuropathy[J].Diabetes Res Clin Pract, 1994, 24(3)∶173～180
8 Toyota T, Hirata Y, Ikeda Y, et al. Lipo-PGE1, a newlipid-encapsulated preparation of prostaglandin E1：placebo-and prostaglandinE1-controlled multicenter trials in patients with diabetic neuropathy and legulcers[J]. Prostaglandins, 1993, 46(5)∶453～468
9 Mizushima Y, Yanagawa A, Hoshi K, et al. prostaglandin E1 is more effective,when incorporated in lipid microspheres, for treatment of peripheral vascular disease inman[J].J Pharm Pharmacol, 1983, 35(3)∶666～667
收稿：2000-02-24修回：2000-05-08
